<DOC>
	<DOCNO>NCT02765399</DOCNO>
	<brief_summary>This study aim evaluate mechanism underlie effect incretin therapy lipoprotein metabolism subject type 2 diabetes study effect liraglutide hepatic de novo lipogenesis .</brief_summary>
	<brief_title>The Effect Liraglutide Treatment Postprandial Chylomicron VLDL Kinetics , Liver Fat de Novo Lipogenesis</brief_title>
	<detailed_description>The well recognize dyslipidemia people type 2 diabetes consist high fast non-fasting plasma triglyceride ( TG ) , low high-density lipoprotein ( HDL ) -cholesterol preponderance small dense low-density lipoprotein ( LDL ) particles nominate atherogenic lipid triad . Humans mostly postprandial rather fast state therefore non-fasting TG value reflect accurately continuous exposure arterial wall triglyceride rich lipoprotein ( TRLs ) importantly , substantial cholesterol load particles deliver . Postprandial lipemia highly prevalent even type 2 diabetes patient normal fast TG concentration . Intestinal overproduction chylomicron ( CMs ) structural protein apolipoprotein ( apo ) -B48 identify integral feature postprandial lipemia type 2 diabetes insulin resistance . It clinically important elucidate mechanism delay postprandial lipemia interaction dysglycemia dyslipidemia type 2 diabetes patient .</detailed_description>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects type 2 diabetes treat lifestyle metformin ( dose ) waist circumference &gt; 88 cm woman &gt; 92 cm men BMI 2740 kg/m2 triglycerides 1.0 4.0 mmol/L LDL &lt; 4.5 mmol/l Type 1 diabetes Apo E2/2 phenotype ALT/AST &gt; 3x ULN GFR &lt; 60 ml/min , clinically significant TSH outside normal range Lipidlowering drug statin within 6 month Current treatment pioglitazone , insulin , sulphonylureas , gliptins , glinides , SGLT2 inhibitor thiazide diuretic ( dose &gt; 25 mg / day ) Blood pressure &gt; 160 mmHg systolic and/or &gt; 105 diastolic History pancreatitis stomach / major bleeding , thyroid neoplasia , persistent hypothyroidism persistent hyperthyroidism Any medical condition put patient risk dehydration Concurrent medical condition may interfere interpretation efficacy safety data study . Females childbearing potential use adequate contraceptive method Subjects experienced sideeffects previously GLP1 agonists Noncompliance withdrawal consent Any information clinical event describe liraglutide SPC contraindication use liraglutide</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>